Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Avastin vs. Lucentis: trialling a blindness prevention drug

Both Avastin and Lucentis have been proven to treat wet AMD, but where do Roche’s priorities lie? Giving a long-lasting debate new fuel, Drug Development Technology looks into the US CATT and UK's IVAN trial to find out how the far cheaper cancer drug Avastin could challenge the monopoly of the wet AMD drug Lucentis.

Go Top